Supportive Care in Cancer

, Volume 14, Issue 5, pp 400–407 | Cite as

Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy

  • Carla Ripamonti
  • Elena Fagnoni
  • Tiziana Campa
  • Cinzia Brunelli
  • Franco De Conno
Supportive Care International

Abstract

Background

World Health Organization (WHO) guidelines, Agency for Health Care Policy and Research (AHCPR) clinical practice guidelines, and EAPC recommendations indicate oral route of opioid administration as the preferred route. Transdermal administration of opioids is considered an alternative when patients cannot take medications orally. Moreover, WHO and EAPC indicate orally administered morphine as the first-choice drug for the treatment of moderate to severe cancer-related pain. However, we can see that in Italy there is an increasing use of transdermal fentanyl (TF) as first-choice strong opioid (and route) even when oral administration of opioids is possible.

Aims

The aims of this study are to describe the modality in the use of TF administration in two settings of care, taking into consideration (1) the drugs previously taken by the patients, (2) the reasons for switching from any drug to TF, (3) the conversion ratio used, and (4) the frequency of “inappropriate use of transdermal fentanyl according to the WHO guidelines and the EAPC recommendations”, i.e., switching to fentanyl patch from any drug, even if there were no contraindications in using oral morphine. The settings of care considered were the out-patient palliative care unit (OP-PCU) and the oncological wards (OWs) of the National Cancer Institute (NCI) of Milan.

Patients and methods

The clinical charts of 98 patients prescribed with and given fentanyl patch for the first time at the NCI of Milan in 2002 were reviewed and the data gathered were grouped according to the administration of fentanyl at the OP-PCU (63 out-patients) or at the OWs (35 in-patients). Summary descriptive statistics and bar and box plots have been used. Fisher two-tailed exact text was applied to test the differences between in- and out-patients.

Results

Before switching to TF, (1) in-patients were more frequently treated with nonsteroidal anti-inflammatory drugs (NSAIDs) and weak opioids (mostly tramadol) in respect to the out-patients (44.1 vs 25.8%) who were mostly treated with oral morphine (48.4 vs 20.6%) (p=0.045), and (2) 88.7% of the out-patients were treated with oral opioids and only 1.6% with parenteral opioids in respect to OWs where 69.7% were on oral opioids and 18.2% on parenteral opioids (p=0.006). In 29% of out-patients and in 53% of in-patients, changing to fentanyl patch was considered as “inappropriate” (p=0.028) according to the WHO guidelines and the EAPC recommendations. No statistically significant differences between the two settings were observed regarding the reasons for switching and the conversion ratio used.

Conclusions

There is a trend to use fentanyl patch as first-choice strong opioid in cancer patients in situations such as titration phase, in the presence of instable pain, and in the absence of dysphagia or gastrointestinal symptoms where the use of oral morphine is, however, not contraindicated.

Keywords

Cancer Pain Oral morphine Transdermal fentanyl Switching Titration Settings of care Opioid administration 

References

  1. 1.
    World Health Organization (1986) Cancer pain relief. World Health Organization, Geneva, SwitzerlandGoogle Scholar
  2. 2.
    World Health Organization (1996) Cancer pain relief, 2nd edn. World Health Organization, Geneva, SwitzerlandGoogle Scholar
  3. 3.
    World Health Organization (1999) Model list of essential drugs (EDL), 11th edn. Available at http://www.who.int/medicines/organization/par/edl/infed 111 group.litml
  4. 4.
    Hanks GW, De Conno F, Ripamonti C et al (Expert Working Group of the European Association for Palliative Care) (1996) Morphine in cancer pain: modes of administration. BMJ 312:823–826Google Scholar
  5. 5.
    Hanks GW, De Conno F, Cherny N et al (Expert Working Group of the Research Network of the European Association for Palliative Care) (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84(5):587–593PubMedCrossRefGoogle Scholar
  6. 6.
    Jacox A, Carr DB, Payne R et al (Agency for Health Care Policy and Research (AHCPR) Pharmacological Management) (1994) Recommendations. In: Management of cancer pain. Clinical Practice Guideline No 9. U.S. Department of Health and Human Services, Public Health Service, AHCPR Publication No 94-0592, March, RockvilleGoogle Scholar
  7. 7.
    Gourlay GK (2001) Treatment of cancer pain with transdermal fentanyl. Lancet Oncol 2:165–172PubMedCrossRefGoogle Scholar
  8. 8.
    Chinellato A, Terrazzani G, Walley T, Giusti P (2003) Opioids in Italy: is marketing more powerful than the law? Lancet 362:78PubMedCrossRefGoogle Scholar
  9. 9.
    De Conno F, Ripamonti C, Brunelli C (2005) Opioid purchases and expenditure in nine western European countries. “Are we killing off morphine?” Palliat Med 19:179–184PubMedCrossRefGoogle Scholar
  10. 10.
    Radbruch L, Nauck F, Sabatowski R (2002) Germany: Cancer pain and palliative care—current situation. J Pain Symptom Manage 24(2):183–187PubMedCrossRefGoogle Scholar
  11. 11.
    Kornik CA, Santiago-Palma J, Moryl N, Payne R (2003) Benefit–risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 26(13):951–973CrossRefGoogle Scholar
  12. 12.
    Skaer TL (2004) Practice guidelines for transdermal opioids in malignant pain. Drugs 64(23):2629–2638PubMedCrossRefGoogle Scholar
  13. 13.
    Scottish Intercollegiate Guidelines Network (SIGN) (2000) Cancer pain guidelines. SIGN, EdinburghGoogle Scholar
  14. 14.
    Gourlay GK, Kowalski SR, Plummer JL et al (1989) The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. Pain 37:193–202PubMedCrossRefGoogle Scholar
  15. 15.
    Korke W, de Stoutz N, Morant R (1996) Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 11:139–146CrossRefGoogle Scholar
  16. 16.
    Portenoy RK, Southam MA, Gupta SK et al (1993) Transdermal fentanyl for cancer pain: repeated dose pharmacokinetics. Anesthesiology 78:36–43PubMedCrossRefGoogle Scholar
  17. 17.
    Varvel JR, Shaker SL, Hwang SS et al (1989) Absorption characteristics of transdermally administered fentanyl. Anesthesiology 70:928–934PubMedCrossRefGoogle Scholar
  18. 18.
    Holley FO, Van Steennis C (1988) Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate IV and transdermal delivery: Br J Anaesth 60:608–613PubMedCrossRefGoogle Scholar
  19. 19.
    Gourlay GK, Kowalski SR, Plummer JL et al (1990) The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain 20:21–28CrossRefGoogle Scholar
  20. 20.
    Mystakidou K, Befon S, Kouskouni E, Gerolymatos K, Georgaki S, Tsilika E, Vlahos L (2001) From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Anticancer Res 21:2225–2230PubMedGoogle Scholar
  21. 21.
    Burza M, Ginobbi P, Fusco G, Laurenzi L, Tirelli W, Arcuri E (1998) Transdermal route as an alternative to oral administration of opioids in cancer pain. Clin Ter 149(4):277–280PubMedGoogle Scholar
  22. 22.
    Van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WWA (2003) Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 19(6):457–469PubMedCrossRefGoogle Scholar
  23. 23.
    Tawfik MO, Bryuzgin V and Kourteva G (FEN-INT-20 Study Group) (2004) Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin 20(3):259–267PubMedCrossRefGoogle Scholar
  24. 24.
    Vielvoye-Kerkmeer A, Mattern C, Uitendaal MP (2000) Transdermal fentanyl in opioid-naïve cancer patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naïve patients and a group using codeine. J Pain Symptom Manage 19:185–192PubMedCrossRefGoogle Scholar
  25. 25.
    Janssen, LP (2005) Important drug warning. http://www.fda.gov/medwatch/SAFETY/2005/duragesic_ddl.pdf
  26. 26.
    Megens A, Artois K, Vermeire J et al (1998) Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 15:253–257PubMedCrossRefGoogle Scholar
  27. 27.
    Ahmedzai S, Brooks D (1997) Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life—the TTS-fentanyl Comparative Trial Group. J Pain Symptom Manage 13:254–261PubMedCrossRefGoogle Scholar
  28. 28.
    Donner B, Zenz M, Tryba M et al (1996) Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 64:527–534PubMedCrossRefGoogle Scholar
  29. 29.
    Payne R, Mathias SD, Pasta DJ et al (1998) Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 16:1588–1593PubMedGoogle Scholar
  30. 30.
    Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V (Expert Working Group the Research Network of EAPC) (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542–2554PubMedGoogle Scholar
  31. 31.
    Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, Lehmann KA (2000) Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 14:111–119PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Carla Ripamonti
    • 1
  • Elena Fagnoni
    • 1
  • Tiziana Campa
    • 1
  • Cinzia Brunelli
    • 1
  • Franco De Conno
    • 1
  1. 1.Rehabilitation and Palliative Care Operative UnitNational Cancer InstituteMilanItaly

Personalised recommendations